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LETTERS TO THE EDITOR
What Is the Mechanism of Abnormal
Blood Pressure Response on
Exercise in Hypertrophic Cardiomyopathy?
Ciampi et al. (1) recently reported a study on the mechanism of
abnormal blood pressure response (ABPR) on exercise in hyper-
trophic cardiomyopathy (HCM). Their study suggests that ABPR
is due to a profound impairment of cardiac output augmentation
on exercise. Cardiac output was measured using a portable nuclear
detector (nuclear VEST). Their results are in marked contrast to
two previous published studies carried out by us.
In the first study Frenneaux et al. (2) evaluated cardiac output
changes invasively and showed that ABPR was due to an exag-
gerated fall in systemic vascular resistance rather than a failure of
cardiac output to increase appropriately. In the second study we
showed that in patients with ABPR there was vasodilation in
nonexercising vascular beds instead of the “normal” vasoconstrictor
response (3). In the study by Ciampi et al. (1) we note that in all
three groups of subjects (healthy controls, HCM, and ABPR
HCM) cardiac output responses to exercise are markedly lower
than would be expected from the published data. Furthermore, the
HCM patients with ABPR have only marginally lower exercise
duration than do subjects with a normal blood pressure response.
Yet, in contrast, these patients demonstrate a dramatically lower
cardiac output response.
The group with ABPR performed 8 min of exercise on a Bruce
protocol. This should equate to a VO2 peak of approximately 20 to
25 ml/kg/min, which is similar to the measurement we have
observed in an analogous group of patients with ABPR. In
contrast, the observed increase in cardiac output of only 50% would
be anticipated to lead to a VO2 peak of only 9 to 10 ml/kg/min. We
should comment that we have tested the nuclear VEST technique
for measuring cardiac output changes during exercise. The values
we obtained were implausibly low, and we therefore abandoned the
technique.
To the best of our knowledge, cardiac output measurements
during exercise using the cardiac VEST technique have not been
validated against established invasive measurements. Moreover, to
ensure that the VEST was correctly positioned over the left
ventricle (LV), the VEST detector was placed under gamma
camera control with a 30-s static imaging obtained at the end of
exercise (1). These control measures, however, were made in the
supine position. Because exercise was performed in the upright
posture, it is quite likely that some degree of displacement of the
VEST relative to the LV took place. Although we greatly respect
the work of this group, we suggest that the nuclear VEST cardiac
data are incompatible with the observed exercise duration of these
patients and that this must be due to an inherent inaccuracy of the
technique during exercise, as used by both Ciampi et al. (1) and
ourselves. Furthermore, given the very similar treadmill exercise
duration of the HCM patients with and without ABPR, the
hugely different cardiac output responses are unlikely to be valid.
These observations suggest that the technique cannot even be used
for the assessment of qualitative rather than quantitative differ-
ences.
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REPLY
We read with great interest Dr. Campbell’s letter. His points rely
basically on one statement and two syllogisms. The statement is
that the VEST technique is inadequate in measuring cardiac
hemodynamics. The syllogisms are that, hence, our findings (1) are
inaccurate and, thus, their conclusions (2,3) are correct. We will try
to dispute the statement and the first syllogism.
As for the statement, various studies have evaluated the accuracy
and the reproducibility of measurements obtained by VEST (4–7).
In our laboratory, Pace et al. (8) demonstrated that the VEST-
derived values of ejection fraction and peak filling rate are accurate
and repeatable (8). Imbriaco et al. (9) showed that VEST is
accurate in measuring cardiac hemodynamic responses to different
cardiac stimulations (handgrip, tilt test, and nitrate administra-
tion). The researchers measured changes from baseline to peak
response in ejection fraction, stroke volume, and cardiac output,
and they found that these changes are similar in two different
studies (coefficient of repeatability: 7.0, 7.0, and 7.6, respectively).
Dr. Campbell is correct in saying that a validation of VEST-
measured cardiac output in comparison with invasive techniques
has never been performed; this is not crucial, though. The
VEST does not measure absolute cardiac output; rather, it
measures changes relative to baseline, and these changes are
reproducible (9). In addition, measurements are derived from
counts and are geometry-independent; therefore, exercise-
induced changes in left ventricular (LV) shape would not affect
the accuracy of measurements.
Second, VEST monitoring has also been used by others to
assess LV function changes during routine activities and could
detect silent ischemic episodes (10–12). Follow-up demonstrated a
highly significant relationship between the occurrence of silent LV
dysfunction, assessed by VEST, and cardiac events (13,14). Kay-
den et al. (15) monitored LV systolic function by VEST during left
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anterior descending coronary angioplasty. The investigators
showed a fall in ejection fraction during balloon inflation, with an
increase in end-systolic volume. During VEST monitoring, Volpe
et al. (16) showed that cardiac adaptations to acute volume loading
are compromised in patients with dilated cardiomyopathy. A drop
in ejection fraction occurred during exercise and mental stress test
in hypertensive patients with LV hypertrophy, as compared to a
nearly normal response in patients without hypertrophy (17,18).
Two studies demonstrated that LV dysfunction during exercise or
dobutamine infusion is a common phenomenon in patients with
hypertrophic cardiomyopathy (HCM), and these studies postu-
lated that it was due to myocardial ischemia (19,20). Finally, our
group studied the hemodynamic adaptation by VEST during
handgrip in patients with HCM with or without obstruction (21)
and also during head-up tilt test in patients with and without
history of syncope (22). To the best of our knowledge, no fewer
than 64 studies have evaluated LV hemodynamics by using VEST
monitoring in various cardiac diseases and settings. All these
studies have shown that hemodynamic changes by VEST correlate
well with an array of physiological and clinical findings.
Third, Dr. Campbell reports that investigators had “implausibly
low” cardiac output changes during exercise with VEST and
“abandoned the technique.” It is suggested that in our study the
“implausibly low” cardiac output changes are due to unnoticed
displacement of the device relative to the left ventricle, as exercise
was performed in the orthostatic position and positioning of the
device in the supine position. We respectfully disagree: positioning
of the device was performed in the orthostatic position. Although
this was not clearly stated in our report (1), we referred to a
previous study for technical details (4). Because VEST position
was checked twice—before and at the end of the study—it is
unlikely that it was correct at the beginning and at the end of the
protocol, but not during it. Besides, as outlined in our report, a
sudden shift 10% in the average counts was considered a sign of
inadequate data acquisition (as it is associated with detector’s
movement or malfunction [4,8]).
As for syllogism, in our study (1), maximum increase in cardiac
output was not reported: data reflect changes in cardiac output at
peak exercise. Because cardiac output rises to a given level of
exercise, it then declines (slightly in controls and more in patients);
thus, reported increase in cardiac output is less than the maximum.
We do not consider the actual increase in cardiac output to be
implausibly low in our sedentary controls: maximum cardiac
output ranged from 162% to 377% of baseline, with a mean of 230
 67%. Even if there was a systematic underestimation of cardiac
output changes during exercise, it would be impossible to explain
solely on the basis of such hypothetical (and in our view unproved)
underestimation why patients with HCM and abnormal blood
pressure response (ABPR) to exercise would increase cardiac
output less than would controls and patients with HCM and
normal blood pressure response.
Second, Dr. Campbell performs an estimate of peak oxygen
consumption based on the duration of exercise. It is not clear to us
how that can be accomplished. In a series of 28 patients with
HCM in whom expired gases were analyzed during exercise, we
found no correlation between exercise duration in minutes and
peak or % of predicted oxygen consumption (r  0.31, p  0.11;
r  0.22, p  0.25, respectively). If exercise duration was an
accurate estimate of peak oxygen consumption, we wonder why
anyone would measure expired gases. Although we concur that
peak oxygen consumption is related to cardiac output, we believe
that exercise duration bears no correlation with cardiac output. In
the above-mentioned series of 28 patients, only one patient had
exercise-induced hypotension, and 9 patients had a flat blood
pressure response to exercise. In these patients, peak oxygen
consumption was significantly less than in patients with HCM and
normal blood pressure response to exercise (% of predicted: 73 
14 vs. 93  25%, p  0.027). A paper from St. George’s Hospital
Medical School dealt with oxygen consumption in HCM (23):
interestingly, investigators found that patients with ABPR had
lower peak oxygen consumption than did those with normal
response. These data are in agreement with ours, and they are
consistent with a blunted cardiac output increase in that subgroup
of patients. Furthermore, a study appeared in JACC a few years ago
outlining a mechanism for ABPR to exercise in HCM that is
consistent with our data: Yoshida et al. (23) proved that those
patients are the ones in whom a greater degree of exercise-induced
subendocardial ischemia develops.
In conclusion, we believe that the discrepancy between our
study (1) and the studies by Frenneaux et al. (2,3) exists, but it
cannot be explained on the basis of an inadequacy of VEST in
measuring cardiac hemodynamics, as we had outlined in the
Discussion section of our original report.
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Beneficial Effects of Simvastatin
and Pravastatin on Cardiac
Allograft Rejection and Survival
In their study comparing beneficial effects of simvastatin and
pravastatin on cardiac allograft rejection and survival, Mehra et al.
(1) concluded both statins to be equivalent and superior to
no-statin treatment. Clinical trials whose purpose are to show
equivalence/noninferiority of two or more treatments commonly
apply methods to demonstrate superiority and, if no statistical
differences are found, treatments are assumed to be equivalent. The
correct approach, however, would be to calculate sample sizes using
bio-equivalence formulae (2). Although the findings of the statin
trial are reassuring, the study could have been underpowered.
Could the investigators comment on power-size calculation prior
to this study and whether the concept of equivalence testing was
adhered to?
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REPLY
I am grateful to Dr. Conraads for the opportunity to respond to the
issues raised and am pleased to note that our findings provide
reassurance to our colleague in the comparative usefulness of either
simvastatin or pravastatin following cardiac transplantation. Ever
since the original publication by Kobashigawa et al. (1), wherein
the beneficial immunomodulating properties of pravastatin on
indices of cardiac allograft rejection were reported, it has remained
an enigma whether other drugs within the class share this property.
Assuming a 25% incidence of allograft rejection requiring treat-
ment at one year, given the cohort size, the current study had 80%
power to detect a 15% difference in rejection rates between either
pravastatin or simvastatin, with a type-1 error of 0.05. Thus, based
on our results, it is unlikely that pravastatin is superior to
simvastatin in abrogating cardiac allograft rejection.
Insofar as the issue of survival is concerned, we agree that the
study could have been underpowered as a single-center experience
is unlikely to enroll the requisite number of transplants that would
be required to confirm or refute a difference in survival alone.
Nevertheless, we must emphasize that the survival rates in our
study (92% and 91% for pravastatin and simvastatin, respectively)
are in agreement with those previously reported by other single-
center studies (95%) of statins (1) and superior to those reported by
multicenter registry databases (83%) that have a relatively low
penetration of statin use (2). Because allograft rejection is the
prime driver of survival in the first year, we strongly believe that
our study should restore confidence in the similar safety and
efficacy of low-dose statin therapy and steer us toward a more
universal use of these agents to enhance outcomes in cardiac
transplantation.
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